C000012122 Fees and Costs — PGIM Jennison Health Sciences Fund, Class B
Data updated: 2026-07-27
The net expense ratio is 2.22%: a 0.72% management fee, a 1.00% 12b-1 fee plus 0.50% other expenses. This share class carries a deferred sales charge of up to 5.00%. In fiscal 2025 the fund paid $1.0M in broker commissions, 0.0692% of average net assets, and portfolio turnover was 81%.
C000012122 Fees and Expenses
Annual operating expenses and sales charges of C000012122. Prospectus, as of January 31, 2020.
| Annual operating expenses | |
|---|---|
| Management fee | 0.72% |
| 12b-1 fee | 1.00% |
| Other expenses | 0.50% |
| Gross expense ratio | 2.22% |
| Fee waiver | — |
| Net expense ratio | 2.22% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | 5.00% |
| Redemption fee | 0.00% |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
C000012122 Costs Over Time
On $10,000 invested in C000012122, assuming 5% a year before costs, total costs come to $1,395 over 5 years, cutting the return by 2.40% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Sales charges | $513 | $0 | $0 |
| Fund expenses (net expense ratio 2.22%) | $233 | $718 | $1,228 |
| Trading costs (broker commissions) | $7 | $22 | $38 |
| Lost growth on money paid in costs | $0 | $37 | $130 |
| Total costs | $753 | $777 | $1,395 |
| Value after costs | $9,747 | $10,799 | $11,367 |
| Impact on return, per year | 7.53% | 2.40% | 2.40% |
C000012122 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending November 30, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0692%
- Total broker commissions: $1.0M
- Bought from dealers (principal trades, not a cost): $47.9M
- Portfolio turnover (prospectus): 81%
- Securities on loan, average value: $57.9M
- Net income from securities lending: $822K (0.055% of average net assets)
C000012122 Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| JEFFERIES LLC | $123K | 18.81% |
| SVB Leerink LLC | $99K | 15.12% |
| BOFA SECURITIES, INC. | $72K | 10.93% |
| J.P. MORGAN SECURITIES LLC | $67K | 10.25% |
| EVERCORE GROUP L.L.C. | $60K | 9.22% |
| GOLDMAN SACHS & CO. LLC | $53K | 8.05% |
| CAPITAL INSTITUTIONAL SERVICES, INC | $49K | 7.54% |
| TD SECURITIES (USA) LLC | $49K | 7.51% |
| WELLS FARGO SECURITIES, LLC | $46K | 6.98% |
| KEYBANC CAPITAL MARKETS, INC. | $37K | 5.60% |
C000012122 Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| BOFA SECURITIES, INC. | $17.0M | 35.43% |
| JEFFERIES LLC | $10.8M | 22.48% |
| GOLDMAN SACHS & CO. LLC | $10.0M | 20.80% |
| SVB Leerink LLC | $6.7M | 13.94% |
| J.P. Morgan Securities LLC | $2.7M | 5.62% |
| MORGAN STANLEY & CO. LLC | $824K | 1.72% |
PGIM Jennison Health Sciences Fund Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| PHLQX | Class R6 | 0.80% | none |
| PHSZX | Class Z | 0.88% | none |
| PHLAX | Class A | 1.15% | 5.50% |
| PJHRX | Class R | 1.48% | none |
| PHLCX | Class C | 1.97% | none |
| C000012122 | Class B | 2.22% | none |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.